Hepcvir L Tablet

Most side effects of Hepcvir L Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

• Headache 
• Nausea 
• Insomnia 
• Fever
• Chills
• Muscle pain
• Cramps
• Tiredness
• Diarrhea 
• Fainting 
• Loss of appetite
• Skin rash
• Itching
• Irritability

Hepcvir L Tablet contains Ledipasvir and Sofosbuvir. Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. 

Thorough QT studies have been conducted for Sofosbuvir/Ledipasvir. The effect of Ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was calculated in a randomized, multiple-dose, placebo- and active-controlled (moxifloxacin 400 mg), three-period, crossover thorough QT trial in 59 healthy subjects. At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), Ledipasvir does not prolong the QTc interval to any clinically relevant extent.

The effect of Sofosbuvir 400 mg (maximum recommended dosage) and 1,200 mg (three times the maximum recommended dosage) on QTc interval was calculated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg), four-period, crossover thorough QT trial in 59 healthy subjects. At a dose three times the maximum recommended dose, Sofosbuvir does not prolong QTc to any clinically relevant extent.

• ​Take the next scheduled dose if you miss a dose (if it is already the time for your next dose).
• Do not double the dose strength in order to catch up.​
  

• Alshoaibi IA, Al-Gamli A, Abdullah M, Abdo B, Alzanen KH, Alhakamy M, Al-Namer M, Ahmed F, Tamesh M, Mahdi W, Abdo Z, Mohammed M.(2024).  Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study. Cureus - https://pubmed.ncbi.nlm.nih.gov/39350869/
• Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J. (2019). Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One. - https://pubmed.ncbi.nlm.nih.gov/30946776/
  
• Değertekin B, Demir M, Akarca US, Kani HT, Üçbilek E, Yıldırım E, Güzelbulut F, Balkan A, Vatansever S, Danış N, Demircan M, Soylu A, Yaras S, Kartal A, Kefeli A, Gündüz F, Yalçın K, Erarslan E, Aladağ M, Harputluoğlu M, Özakyol A, Temel T, Akarsu M, Sümer H, Akın M, Albayrak B, Sen İ, Alkım H, Uyanıkoğlu A, Irak K, Öztaşkın S, Uğurlu ÇB, Güneş Ş, Gürel S, Nuriyev K, İnci İ, Kaçar S, Dinçer D, Doğanay L, Göktürk HS, Mert A, Coşar AM, Dursun H, Atalay R, Akbulut S, Balkan Y, Koklu H, Şimşek H, Özdoğan O, Çoban M (2025).
  
• Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Turk J Gastroenterol. 31(12):883-893 - https://pubmed.ncbi.nlm.nih.gov/33626001/
• Katiyar H, Kamat M, Mandot AK, Goel A, Singh S, Mishra AK, Singh R, Tiwari P, Dhiman RK, Shah S.(2024). Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India. J Clin Exp Hepatol  - https://pubmed.ncbi.nlm.nih.gov/38261859/
  
• Manabe T, Tadokoro T, Nakahara M, Ohura K, Fujita K, Tani J, Morishita A, Ogawa C, Masaki T.(2024). Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir. Intern Med. 62(17):2507-2511 - https://pubmed.ncbi.nlm.nih.gov/36450472/
  
• Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V.(2019), Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatol Int. 13(2):173-179. - https://pmc.ncbi.nlm.nih.gov/articles/PMC8311524/
  
• Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. (2021). Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infect Dis Ther. 10(1):269-280. Epub 2020 Nov 3.​